Skip to main content
Image
Michael Schöll
Breadcrumb

Michael Schöll Group

Research group
Active research
Project period
2017 - ongoing
Project owner
University of Gothenburg

Short description

Michael Schöll, PhD, is an Associate Professor in molecular medicine with focus on neuroimaging.

About Michael Schöll Group

Neurodegenerative diseases are notoriously difficult to diagnose early and there is still no cure available for dementia disorders such as Alzheimer’s disease (AD). Biomarkers derived from imaging modalities such as positron emission tomography (PET) and magnetic resonance imaging (MRI), as well as biomarkers based on the analysis of cerebrospinal fluid (CSF) or blood, have become immensely important especially for the early identification of individuals who are likely to develop a neurodegenerative disorder, since an established notion is that potentially successful treatments should be deployed as early as possible in the disease process.

This early identification of neuropathological processes using adequate biomarkers currently not only supports reliable clinical diagnoses but also serves the recruitment of suitable candidates for clinical treatment trials, and renders possible the application of these biomarkers as outcome measures in treatment trials.

In particular the recent development of methods to map the accumulation of conformationally faulty forms of proteins and the subsequent synaptic impairment in vivo using PET has profoundly changed the way these processes can be identified at an early, presymptomatic disease stage. The Schöll group is using the most recent developments in molecular imaging by means of PET in combination with other neuroimaging- and fluid-based biomarkers, as well as neuropsychological profiling to develop holistic, validated, and usable tools for such an early identification.

Collaborations

The establishment of the Schöll group was strongly coupled with the recent inauguration of the Imaging- and Intervention Center (Bild- och Interventionscentrum – BoIC) at the Sahlgrenska University Hospital, which for the first time offers resources for research involving molecular imaging modalities in West Sweden.

The group has furthermore established extensive national collaborations with researchers and clinicians at the University of Gothenburg / The Sahlgrenska University Hospital, and with researchers at Lund University, the Karolinska Institute, and Umeå University. Internationally, the group collaborates actively, amongst others, with researchers at the University of California, Berkeley, University College London, Stanford University, and McGill University

Michael Schöll - portrait
Photo: Johan Wingborg

Contact Information

Michael Schöll
michael.scholl@neuro.gu.se

Department of Psychiatry and Neurochemistry
Sahlgrenska University Hospital
Blå stråket 15, 3rd floor
Gothenburg, Sweden

Visiting Addresses:
Sahlgrenska University Hospital

MedTech West
Röda Stråket 10B
413 45 Gothenburg

Memory Clinic
Wallinsgatan 6
431 41 Mölndal

News from the group

Michael Schöll invited to speak at charity event of the Swedish Brain Foundation

On the 20th of October, the Swedish Brain Foundation organized a charity dinner in Stockholm. As part of this event, Michael Schöll was invited to speak about the ongoing Sahlgrenska NeuroCOVID Study. The aim of this study is to map neurological sequela in COVID-19 patients over time.

Group Members

Photo: Malin Arnesson

Eva Bringman, Research Coordinator

Email

Eva Bringman is a registered nurse with long experience of clinical research in both healthcare and pharmaceutical industry. She has been working as research coordinator in the field of dementia research at the Department of Neuroscience and Physiology for several years. Joined the Schöll group January 2018

William Jagust, Visiting Professor, University of California, Berkeley

Wiliam Jagust is a professor of neuroscience and public health at the Helen Wills Neuroscience Institute, University of California, Berkeley. He will be a visiting professor at Sahlgrenska Academy, affiliated with the Schöll group 2018-2021.

Michel Grothe, PhD, Senior Research Associate

E-mail

Michel Grothe is a senior researcher at the Movement Disorders Group of the Institute of Biomedicine of Seville (IBiS), Spain, who is specialized in multimodal PET/MRI neuroimaging techniques for studying neurodegenerative disease pathology in-vivo. He joined the Schöll group in 2019 as a senior research associate to supervise research projects focused on novel analytic techniques for studying cortical pathologic patterns in multimodal imaging data, with a particular focus on the integration of regional information form amyloid- and tau-sensitive PET scans.

Tora Dunås, PhD, Research Assistant

E-mail

Tora Dunås has a degree in engineering mathematics and a biomedical engineering from Chalmers University, and a PhD in medical technology from Umeå University. Her main research interests are subjects related to neuroimaging and healthy aging, such as brain maintenance, cerebral blood flow, dementia and cognitive decline.

Iris Bosch, MSc, Research Assistant

Iris has a master’s degree in Brain and Cognitive Sciences from the University of Amsterdam, the Netherlands. She is particularly interested in the usage of neuroimaging techniques to disentangle the pathology of neurodegenerative diseases such as Alzheimer’s disease. Iris graduated with a joint project from the Alzheimer Center Amsterdam and the Department of Radiology & Nuclear Medicine (Amsterdam UMC), where she investigated the predictive value of tau PET and relative cerebral blood flow for atrophy in Alzheimer’s disease.  
At the moment she is working on different projects within the research group, mostly with a focus on neuroimaging.  

Researchers:

Nicholas Ashton, PhD, Senior Researcher

Email

Nicholas Ashton is a researcher joining the team from the Department of Old Age Psychiatry at King’s College London where his research focused on using fluid-based biomarkers to complement quantitative imaging assessments for the early detection of dementia risk. Nicholas has a technical background in Mass Spectrometry and immunological-based assays which has been utilised more recently to develop blood signatures of Alzheimer’s disease neuropathology.

Thomas Vogels, PhD, Researcher

Email

Thomas Vogels is co-founder of the biotech company Maptimmune and affiliated researcher at the Michael Schöll group. His research focusses on developing immunotherapeutics with increased brain uptake for the treatment of Alzheimer’s disease. Within the Schöll group he performs academic research relating to the characterization of tau PET ligands that are currently in clinical use.

Postdoctoral Researchers:

Alexis Moscoso Rial, PhD, Postdoc

E-mail

Alexis Moscoso is a postdoctoral researcher joining Schöll’s lab from the Molecular Imaging Group at the University Hospital of Santiago de Compostela. His research is focused on imaging biomarkers for the detection of the earliest pathological changes in neurodegenerative diseases. Specifically, Alexis has investigated how Positron Emission Tomography imaging biomarkers change in the early phases of Alzheimer Disease, as well as how these markers complement other imaging measures such as those derived from Magnetic Resonance Imaging.

Ambra Dreos, PhD, Postdoc

E-mail

Ambra Dreos is currently doing her PostDoc on a project characterising PET ligands for the study of Alzheimer’s disease pathologies. She earned her PhD in 2019 at Chalmers University (Sweden) with a project on synthesis, spectroscopic characterization, and testing in devices of new organic materials for capture and storage of solar energy. Previously she attended the Organic Chemistry and Biomolecular Chemistry Master program at the University of Trieste (Italy) graduating summa cum laude in 2014. Her Master thesis was conducted at the University of Southern Denmark, with a project on supramolecular chemistry (synthesis and characterization of pseudorotaxanes). Her main expertise is within physical organic chemistry, having been doing both synthesis and physical characterization of complex organic systems with spectroscopy and other techniques (such as NMR, and DSC).

PhD Students:

Fredrik Öhman, PhD Student

Email 

Fredrik Öhman is a PhD student in Michael Schöll's research group and the Institute of Neuroscience and Physiology, Sahlgrenska Academy. Fredrik will use neuropsychology, neuroimaging and neurochemical biomarkers to validate newly developed methods for detecting cognitive impairment in early stage dementia disorders.

Besides Fredrik’s research work, he is a clinical psychologist at the Sahlgrenska University Hospital memory clinic.

Meera Srikrishna, PhD Student

Email

Meera Srikrishna is a PhD student in Schöll group with the Wallenberg Centre for Molecular and Translational Medicine and the Institute of Neuroscience and Physiology, Sahlgrenska Academy. Her research focuses on the application of multimodal image analysis to understand the extent of neurodegeneration. Currently, she is studying deep learning-based techniques to derive biomarkers from neuroimaging modalities. Meera has a technical background in structural and functional MRI data processing and cellular image processing. She pursued her Masters in biomedical engineering and worked in National Brain Research Centre, India between in 2015-17.

Peter Young, MSc, PhD Student

Email

Peter Young is a PhD student joining the team from the Bristol Royal Infirmary where he worked as a medical physicist in the imaging department of the hospital. Peter has a background in medical imaging, radiation physics and radiation protection which he used for the optimisation and new development of imaging techniques within both hospital and research environments.

Associated Researchers:

Emily Jacoby Kask 

Emily is a licensed psychologist with a background in clinical adult treatment and investigation. She works as a research assistant in the group, and helps to perform cognitive testing in the covid study. 

Jennifer Alvén, PhD

Email

Jennifer Alvén completed her PhD within the Computer Vision and Medical Image Analysis research group at the Department of Electrical engineering at Chalmers University of Technology. Jennifer conducted research in the field of medical image analysis with Fredrik Kahl and Olof Enqvist as supervisors. Her research focus is machine learning and explicit/implicit shape models for classification and segmentation of medical 2D and 3D images. Jennifer joined Michael Schöll's research group while she was a PhD student, with focus on applying image registration and signal processing methods on PET and MR.

Kenneth Dahl, PhD

Kenneth is currently working as a Radiochemist at the Sahlgrenska PET Radiopharmacy. He obtained his PhD in the Radiopharmaceutical Chemistry form Karolinska Institutet in 2016, and continued his training within PET Radiochemistry at Massachusetts General Hospital and Harvard Medical School (Boston, USA) as Postdoctoral Researcher. He then worked as a Independent Scientist (2018 – 2020) at the Centre for Addiction and Mental Health (Toronto, Canada). His research interest focuses on developing and translating new chemistry methods and unique PET imaging agents for use in various brain-based illnesses.

Li Lin

Li Lin has a master's degree in neurology from Xuanwu Hospital of Capital Medical University, China. His research focuses on detecting biomarkers and their changes in early stage of Alzheimer's disease. He hopes to identify elderly people who are susceptible to AD. Li has a background in multimodal image analysis and cognitive assessment.

Oleksiy Itsenko, PhD

Email

Oleksiy is principal radiochemist and QP at the Sahlgrenska PET radiopharmacy. Among his key interests are fast labelling reactions and process development. Oleksiy received his PhD in 11C radiochemistry working in the research group of professor Bengt Långström. His experience includes the production of PET tracers for preclinical and clinical use as well as industrial product prototyping.

Putu Ayuwidia Ekaputri  

Putu is a master's student at the Cognitive Neuroscience: Mind and Brain Program at the University of Skövde, Sweden, doing her master’s thesis in the group. She is registered and licensed as Medical Doctor in Indonesia, graduated from the Faculty of Medicine, Universitas Indonesia, in 2015.

Putu has a keen interest in cognitive neuroscience, especially related to psychiatric disorders. In her thesis project, she is investigating the correlation between tau pathology, hypometabolism, and brain atrophy in subjects with Alzheimer’s disease. 

Samuel Berkins

Samuel has a MSc in Biomedical Engineering. He is interested in studying the neurological underpinnings of neurodegenerative disorders like Parkinson and Alzheimers using various imaging modalities. He performed his master thesis at Uppsala University, Sweden to understand the relationship between dietary intake of vitamins and structural brain volume, and its impact on mental health. He has experience in processing and analysing of images acquired from various imaging modalities and is always interested to develop scripts to automate data analysis, data processing etc.

Alumni:

Marie Eckerström, PhD, Psychologist

E-mail

Irena Burmann, PhD, Postdoc

Email

Kerstin Heurling, PhD, Postdoc

Email

Antoine Leuzy, Postdoc

E-mail

Franziska Mauter, BSc, Master's Student

Email

Michihiko Koeda, Visiting Researcher, University of Nippon Medical School, Japan

E-mail

Dimitra Tzaferou, Research Assistant

Group Activities

NeuroPET – September 29-30, 2021

After almost one and a half years of joining conferences from our home offices, kitchen tables or maybe even bedrooms, we were finally able to attend a conference in person again! 

Together we travelled to Umeå to attend NeuroPET 2021, the annual meeting for neuroPET research in Sweden. It was a great pleasure to be able to travel again and come together with fellow researchers from all over Sweden, representing the Universities of Gothenburg, Linköping, Lund, Stockholm, Umeå and Uppsala.

Over the course of two days, we discussed latest findings, current work and future goals, as well as socialized over ‘fika’ and Nordic cuisine inspired meals. We had a great time together and are looking forward to what the future will hold for neuroPET research in Sweden!

Lab Dinner – September 2, 2021

As an end-of-summer get together and to kick off the new academic year, we drank a toast to the semester ahead of us and enjoyed a wonderful lab dinner. We were welcomed by Bord27, a charming little neighborhood restaurant with a great atmosphere and terrific food and drinks. Bring it on 2021/2022!

Summer barbeque – June 10, 2021 

After a long year of working from home, the research group finally had a chance to get together to celebrate this year’s accomplishments with some burgers and beers. The sun was shining, we had a great time, and are now ready to face the rest of the year with renewed energy!

Grant from SciLifeLab/KAW for Covid-19 research 

The Sahlgrenska Collaborative Covid-19 Research Project, with the main applicant Magnus Gisslen, has been granted extended funding through the SciLifeLab National COVID-19 Research Program funded by Knut and Alice Wallenberg Foundation. As a part of this research group, we are studying SARS-CoV-2 in relation to neurological symptoms and their impact on the central nervous system. More specifically, we are investigating the relationship between Covid-19 infection, cognitive impairment, concentrations of biomarkers, and findings on diagnostic neuroimaging. This study has also received grants from Hjärnfonden and Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond, with Michael Schöll as principal investigator.

More information 

PhD course "Biomarkers for neurodegenerative diseases"
May 24-28, 2021 

The third edition of the Biomarkers for neurodegenerative diseases, in collaboration with the UCL Dementia Research Centre, took place between 24-28 May. Due to current circumstances, it was arranged virtually, but both attendance and engagement exceeded all expectations. Over eighty participants from all over the world tuned in, in some places from very early morning to very late night, to take part in lectures and discussions with leading researchers in the field of fluid and imaging biomarkers for Alzheimer’s disease and other neurodegenerative diseases. The delegate reviewed the course overwhelmingly positive, stating that it had been an intense and immensely educational experience with loads of high-quality lectures. The most appreciated part of the course was the Q&A sessions following each lecture, as well as at the end of the course, where the participants could interact with the speakers, leading to many interesting discussions.

Peter Young half-time seminar – February 16, 2021

Peter Young successfully and with fineness passed his half-time seminar with the title Practical Methods to Improve Multimodal Positron Emission Tomographyin Neurology and Neurodegenerative Diseases

Summary: In order to render quantification of PET data usable in a clinical environment, it must be shown to be practical and robust. This has presented problems historically when translating from research to the clinic due the additional requirements for quantification in PET such as complex analysis techniques and scanning procedure standardisation as well as exhaustive validation. This thesis will investigate how novel approaches and analysis techniques can be used to assist in improving the clinical applications of a numbern of different neurological PET modalities. This is with the end goal of making these scans more practical to perform and more robust to interpret in a routine clinical environment.

Christmas Dinner - December 16, 2020

The traditional Molecular Neuroimaging Julbord was held virtually this year - December 16, 2020

Axel Tjörnstrand thesis defence - December 11, 2020

Axel Tjörnstrand, MD, successfully defended his PhD in Medicine entitled Pituitary tumors - epidemiology and the diagnostic value of 68 Ga-DOTATOC PET/CT.

Michael Schöll and group alumna Kerstin Heurling were co-supervisors for his thesis.

Abstract of Thesis
Pituitary neuroendocrine tumors (PitNETs) are considered common in the general population. However benign in most cases, these tumors can evoke dramatic morbidity in patients with aggressive tumor growth and/or excess hormone secretion. Both the primary diagnostic and the post-operative imaging assessment face difficult challenges with today diagnostic methods. Also, modern epidemiological data is scarce in publications regarding these tumors and needs to be updated. The overall aim of this thesis was to study regional PitNET incidence and epidemiological data, and to describe the pre- and post-operative diagnostic properties of 68Ga-DOTATOC-PET.

Paper I was an observational cohort study presenting data from 592 adult PitNET patients living in the Västra Götaland Region diagnosed between 2001-2011. Papers IIIII were prospective, case-controls studies evaluating 68Ga-DOTATOC tracer uptake in patients with PitNETs and healthy control subjects. Uptake data was analyzed in relation to immunohistochemical data of cell type and somatostatin receptor (SSTR) expression. In Paper I, we found the standardized incidence rate (SIR) of PitNETs during the study period was 3.9 cases/100,000/year, which was higher than previously reported from the same region. Non-functioning PitNETs were the most commonly diagnosed (54% of tumors) followed by lactotroph (32%), somatotroph (9%), corticotroph (4%, and thyrotroph (0.7%) tumors. 68Ga-DOTATOC uptake correlated with SSTR2 expression. Tumor uptake was higher in thyrotroph tumors, lower in in gonadotroph and corticotroph tumors in comparison to the uptake in normal pituitary tissue. In tumors with high preoperative tracer uptake (>13.8 SUVmax) the tracer was able to predict clinical remission if post-operative uptake was reduced under 60% of the pre-op scan.

In conclusion, PitNET SIR was higher compared to previously reported data from the same region before MRI became clinical routine. 68Ga-DOTATOC can be used to differentiate corticotroph, gonadotroph, and thyrotroph tumors from normal pituitary gland. Post-operative scans suggest clinical value in predicting remission but need to be studied further.

Fredrik Öhman awarded - November 19, 2020

Fredrik Öhman was awarded the Mannheimer award for junior scientists.

More information [Swedish only]

Photo: Michael Schöll

Doctoral thesis defence by Jennifer Alvén – July 2, 2020

We are very glad to announce that Jennifer Alvén defended her PhD thesis entitled “Combining Shape and Learning for Medical Image Analysis-Robust, Scalable and Generalizable Registration and Segmentation” on the 7th of February 2020. We wish her all the best in her future endeavors!

Abstract of thesis
Automatic methods with the ability to make accurate, fast and robust assessments of medical images are highly requested in medical research and clinical care. Excellent automatic algorithms are characterized by speed, allowing for scalability, and an accuracy comparable to an expert radiologist. They should produce morphologically and physiologically plausible results while generalizing well to unseen and rare anatomies. Still, there are few, if any, applications where today's automatic methods succeed to meet these requirements.

The focus of this thesis is two tasks essential for enabling automatic medical image assessment, medical image segmentation and medical image registration. Medical image registration, i.e. aligning two separate medical images, is used as an important sub-routine in many image analysis tools as well as in image fusion, disease progress tracking and population statistics. Medical image segmentation, i.e. delineating anatomically or physiologically meaningful boundaries, is used for both diagnostic and visualization purposes in a wide range of applications, e.g. in computer-aided diagnosis and surgery.

The thesis comprises five papers addressing medical image registration and/or segmentation for a diverse set of applications and modalities, i.e. pericardium segmentation in cardiac CTA, brain region parcellation in MRI, multi-organ segmentation in CT, heart ventricle segmentation in cardiac ultrasound and tau PET registration. The five papers propose competitive registration and segmentation methods enabled by machine learning techniques, e.g. random decision forests and convolutional neural networks, as well as by shape modelling, e.g. multi-atlas segmentation and conditional random fields.

Keywords: medical image segmentation, medical image registration, machine learning, shape models, multi-atlas segmentation, feature-based registration, convolutional neural networks, random decision forests, conditional random fields

Christmas Dinner – December 12, 2019

A special group gathering to celebrate the Christmas season and get in the festive spirit! This year we had our Christmas dinner at the Chalmersska Huset, an extraordinary venue with fine dining and great history, located in the heart of Gothenburg. It was a lovely evening which included traditional Swedish buffet, wine and a warm atmosphere. Much fun was had by all!

Molecular Neuroimaging Lab Retreat 2019 – November 25-26 2019

Our annual lab retreat was facilitated at Marstrands Havshotell on the 25th-26th of November. We had the pleasure of hosting distinguished external collaborators from universities and research institutions around the world. Our guest list included Dr. David Berron from University of Lund, Sweden, Dr. Andréa Lessa Benedet from McGill Univeristy, Canada, Alexis Moscoso from University of Santiago de Compostela, Spain, as well as Dr. Anne Maass and Dr. Michel Grothe from the German Center for Neurodegenerative Diseases (DZNE).

After we arrived at the hotel, we had coffee and then an early Swedish lunch. In the conference room, all the Group members and the external guests presented their current projects, expertise and research interests. Soon after the individual presentations we had an amazing guided tour of Carlstens fortress followed by some relaxation time in the hotel spa. Alongside the fun activities, group discussions took place with the aim of identifying potential collaborations. A delicious dinner at the hotel was the best way to finish our productive day!

On the second day of the retreat novel research ideas and proposals were reviewed. New research goals were set and everyone seemed to be excited and delighted by the outcome!

Overall, this retreat combined socializing with promoting engagement in scientific projects between the group members and our guests. It was a great experience and we are already looking forward to the next retreat!

International Presentations

Michael Schöll

Alzheimer’s Association International Conference (AAIC) Denver, USA (2021-07-26, Hybrid Conference):  The ever-changing landscape of Alzheimer’s disease biomarkers (Featured Research Session)
Co-host (William Jagust, MD, PhD), Co-speakers (Melissa Murray, PhD, Thomas Karikari, PhD, Susan Landau, PhD)

Mayo Clinic Neuroscience Seminar Series (2021-06-18) 

Alzheimer’s Association ISTAART Neuroimaging workshop tau PET (2020-10-08)

Genentech, San Francisco (2020-01-13): Biomarkers for tau pathology

Alzheimer's Association International Conference (AAIC) Los Angeles (2019-07-17): Featured Research Session, Biomarkers for tau pathology
Keynote speakers (Suzanne L. Baker, PhD, Claudia Cicognola, PhD, Anne Maass, PhD, Niklas Mattsson, MD, PhD)

Human Amyloid Imaging, Miami (2019-01-16): Head-to-head comparison of [18F]Flortaucipir and [18F]RO948 tau PET ligands

German Centre for Neurodegenerative diseases (DZNE) Magdeburg (2018-12-17): Head-to-head comparison of [18F]Flortaucipir and [18F]RO948 tau PET ligands

Duke-NUS (2018-11-12): Update on what we believe is tau imaging

Stanford University (2018-09-03): Update on what we believe is tau imaging

Nicholas Ashton

Alzheimer’s Association International Conference (AAIC) Denver, USA (2021-07-27, Hybrid Conference): Plasma p-tau231 in the Alzheimer’s disease continuum: a multi-cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application

Geneva Task Force of Tau biomarkers (2019-11): Diagnostic performance of blood biomarkers for Alzheimer's disease.

Catalan Neurological Society, Barcelona, Spain (2019-11): From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer’s Disease.

Alzheimer's Association International Conference (AAIC) Los Angeles, USA (2019-07):
Cerebrospinal fluid synaptic vesicle glycoprotein 2A in Alzheimer’s disease.

The German Association of Psychiatry, Psychotherapy and Psychosomatics (DGPPN) Berlin (2018-12-01):
Blood biomarkers for neurodegeneration; an update.

Michel Grothe

15th International Conference on Alzheimer’s and Parkinson’s Diseases (2021-03-12) 
Data-driven identification of distinct cognitive subtypes in Parkinson’s disease dementia: Association with clinical, genetic, and biomarker characteristics 

Alzheimer’s Association International Conference (AAIC) 2020, (July 27-31, 2020, Virtual Conference):
- Disentangling neurodegeneration subtypes of Alzheimer’s disease using data-driven methods (Featured Research Session: Neurobiological subtypes of Alzheimer’s disease).
- Clinical and neurodegenerative features associated with amyloid-β-negative medial temporal tau deposition as measured by multimodal PET imaging

Alexis Moscoso

Alzheimer’s Association International Conference (AAIC) Denver, USA (2021-07-28, Hybrid Conference): Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation

7th Annual Meeting of the European Academy of Neurology (EAN) (2021-06-19)
Progression of tau pathology across in-vivo stages of regional amyloid deposition

The BRAIN Conference (2021-03-04) 
Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum 

15th International Conference on Alzheimer’s and Parkinson’s Diseases (2021-03-12) 
PET-measured progression of tau pathology across in-vivo stages of regional amyloid deposition 

Alzheimer's Association International Conference (2020):
- Association of white matter hyperintensities with sub-threshold amyloid accumulation (poster)
- Clinical and neurodegenerative features associated with amyloid-β-negative medial temporal tau deposition as measured by multimodal PET imaging (poster)
- Evaluation of different partial volume correction methods for longitudinal tau PET imaging (poster)
- Differential effects of APOE2 and APOE4 alleles on PET-measured amyloid-β and tau deposition in older individuals without dementia (poster)

Meera Srikrishna

Alzheimer’s Association International Conference (AAIC) Denver, USA (2021-07-27, Hybrid Conference): Association of deep-learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases

15th International Conference on Alzheimer’s and Parkinson’s Diseases: Mechanisms, Clinical Strategies and promising Treatments of Neurodegenerative Diseases (2021):
First-level assessment of neurodegeneration using deep-learning based brain CT segmentations and blood-derived measures of neurofilament light

Alzheimer's Association International Conference (2020):
T‐based brain segmentation and volumetry using deep learning methods

SPIE optics and photonics-Emerging topics in Artificial Intelligence 2020 (2020-08-25): Deep learning-based human CT brain segmentation using MRI derived labels.

Thomas Vogels

15th International Conference on Alzheimer’s and Parkinson’s Diseases (2021-03-12) 
AAV vectors to study the functional consequences of neuronal and astrocytic tau pathology using in vivo 2-photon imaging 

AAT-ADPD (2020)

Peter Young

British Nuclear Medicine Society (BNMS) spring meeting (2021-05-18) 
Image-derived input functions from dynamic 15O-water PET scans using penalised reconstruction  
 
Svensk Förening för Nuklearmedicin (SFNM) (2021-05-19) – Awarded best abstract of the 2021 meeting  
Image-derived input functions from dynamic 15O-water PET scans using penalised reconstruction 

15th International Conference on Alzheimer’s and Parkinson’s Diseases (2021-03-12) 
Impact of reduced injected dose on the PET quantification of [18F]RO948 to assess tau pathology in vivo 

Fredrik Öhman

Alzheimer's Association International Conference (AAIC) Los Angeles, USA (2019-07):
Neuropsychology and 99MTC-HMPAO single photon emission computed tomography findings from the Gothenburg MCI study

Publications (WCMTM Affiliation)

For a full list of Michael Schöll’s publications, please refer to Google Scholar

https://scholar.google.com/citations?user=hEHgZxMAAAAJ&hl=de
 

P-tau235: a novel biomarker for staging preclinical Alzheimer's disease.
Lantero-Rodriguez J, Snellman A, Benedet AL, Milà-Alomà M, Camporesi E, Montoliu-Gaya L, Ashton NJ, Vrillon A, Karikari TK, Gispert JD, Salvadó G, Shekari M, Toomey CE, Lashley TL, Zetterberg H, Suárez-Calvet M, Brinkmalm G, Rosa Neto P, Blennow K.
EMBO Mol Med. 2021 Nov 2.
DOI: https://doi.org/10.15252/emmm.202115098. Online ahead of print.

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.

Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, Karikari TK, Hourregue C, Cognat E, Dumurgier J, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, Salvadó G, Shekari M, Operto G, Gispert JD, Minguillon C, Fauria K, Kollmorgen G, Suridjan I, Zimmer ER, Zetterberg H, Molinuevo JL, Paquet C, Rosa-Neto P, Blennow K, Suárez-Calvet M; Translational Biomarkers in Aging and Dementia (TRIAD) study, Alzheimer’s and Families (ALFA) study, and BioCogBank Paris Lariboisière cohort. JAMA Neurol. 2021 Oct 18.
DOI: https://doi.org/10.1001/jamaneurol.2021.3671. Online ahead of print.

Changes in Blood Biomarkers of Brain Injury and Degeneration Following Long-Duration Spaceflight.
Zu Eulenburg P, Buchheim JI, Ashton NJ, Vassilieva G, Blennow K, Zetterberg H, Choukér A.
JAMA Neurol. 2021 Oct 11.
DOI: https://doi.org/10.1001/jamaneurol.2021.3589. Online ahead of print.

Deep learning from MRI-derived labels enables automatic brain tissue classification on human brain CT.
Srikrishna M, Pereira JB, Heckemann RA, Volpe G, van Westen D, Zettergren A, Kern S, Wahlund LO, Westman E, Skoog I, Schöll M
Neuroimage. 2021 Sep 25.
DOI: https://doi.org/10.1016/j.neuroimage.2021.118606 Online ahead of print.

CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study.
Milà-Alomà M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, Salvadó G, Falcon C, Gispert JD, Vilor-Tejedor N, Arenaza-Urquijo EM, Grau-Rivera O, Sala-Vila A, Sanchez-Benavides G, González-de-Echávarri JM, Minguillon C, Fauria K, Niñerola-Baizán A, Perissinotti A, Kollmorgen G, Suridjan I, Zetterberg H, Molinuevo JL, Blennow K, Suárez-Calvet M; the ALFA Study. 
Neurology. 2021 Sep 23. 
DOI: https://doi.org/10.1212/WNL.0000000000012853 Online ahead of print.

Current advances in digital cognitive assessment for preclinical Alzheimer’s disease. 
Öhman F, Hassenstab J, Berron D, Schöll M, Papp KV.
Alzheimer's & Dementia. 2021 Jul 20.
DOI: https://doi.org/10.1002/dad2.12217 Online ahead of print.

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
Grothe MJ, Moscoso A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Schöll M; Alzheimer’s Disease Neuroimaging Initiative.
Neurology. 2021 Jul 15.
DOI: https://doi.org/10.1212/WNL.0000000000012513 Online ahead of print.

A multicentre validation study of the diagnostic value of plasma neurofilament light 
Nicholas J. Ashton, Shorena Janelidze, Ahmad Al Khleifat, Antoine Leuzy, Emma L. van der Ende, Thomas K. Karikari, Andrea L. Benedet, Tharick A. Pascoal, Alberto Lleó, Lucilla Parnetti, Daniela Galimberti, Laura Bonanni, Andrea Pilotto, Alessandro Padovani, Jan Lycke, Lenka Novakova, Markus Axelsson, Latha Velayudhan, Gil D. Rabinovici, Bruce Miller, Carmine Pariante, Naghmeh Nikkheslat, Susan M. Resnick, Madhav Thambisetty, Michael Schöll, Gorka Fernández-Eulate, Francisco J. Gil-Bea, Adolfo López de Munain, Ammar Al-Chalabi, Pedro Rosa-Neto, Andre Strydom, Per Svenningsson, Erik Stomrud, Alexander Santillo, Dag Aarsland, John C. van Swieten, Sebastian Palmqvist, Henrik Zetterberg, Kaj Blennow, Abdul Hye & Oskar Hansson  
Nature Communications. 2021 June 07;12:3400 
doi: https://doi.org/10.1038/s41467-021-23620-z 
 
Tau Seeding Mouse Models with Patient Brain-Derived Aggregates 
Aiko Robert, Michael Schöll, Thomas Vogels 
Int. J. Mol. Sci. 2021 June 07;22(11):6132 
doi: https://doi.org/10.3390/ijms22116132 

Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Jacob W. Vogel, Alexandra L. Young, Neil P. Oxtoby, Ruben Smith, Rik Ossenkoppele, Olof T. Strandberg, Renaud La Joie, Leon M. Aksman, Michel J. Grothe, Yasser Iturria-Medina, the Alzheimer’s Disease Neuroimaging Initiative, Michael J. Pontecorvo, Michael D. Devous, Gil D. Rabinovici, Daniel C. Alexander, Chul Hyoung Lyoo, Alan C. Evans & Oskar Hansson 
Nature Medicine. 2021 April 29;27:871–881
doi: https://doi.org/10.1038/s41591-021-01309-6

Discriminatory ability of next-generation tau PET tracers for Alzheimer’s disease. 
Yap SY, Frias B, Wren MC, Schöll M, Fox NC, Årstad E, Lashley T, Sander K. 
Brain. 2021 March 20. 
https://doi.org/10.1093/brain/awab120 Online ahead of print 

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton NJ, Tharick A. Pascoal, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, Snellman A, Schöll M, Troakes C, Hye A, Gauthier S, Vanmechelen E, Zetterberg H, Rosa-Neto P, Blennow K.
Acta Neuropathol. 2021 Feb 14;141:709–724
doi: 10.1007/s00401-021-02275-6

Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia.
Salvadó G, Grothe MJ, Groot C, Moscoso A, Schöll M, Gispert JD, Ossenkoppele R.
Eur J Nucl Med Mol Imaging. 2021 Feb 1. doi: 10.1007/s00259-021-05192-8. Online ahead of print. PMID: 33521872
doi: 10.1007/s00259-021-05192-8

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-Carlgren N, Schöll M, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Lovestone S, Aarsland D; AddNeuroMed consortium, Hansson O, Rosa-Neto P, Westman E, Blennow K, Zetterberg H, Ashton NJ.
Alzheimers Dement. 2021 Jan 25.
doi: 10.1002/alz.12283. Online ahead of print.

Pre- and postoperative 68 Ga-DOTATOC positron emission tomography for hormone-secreting pituitary neuroendocrine tumors.
Tjörnstrand A, Casar-Borota O, Heurling K, Schöll M, Gjertsson P, Ragnarsson O, Filipsson Nyström H.
Clinical Endocrinology. 2021 Jan 23;94:956–967
doi: 10.1111/cen.14425.

Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter.
Moscoso A, Grothe MJ, Schöll M.
Eur J Nucl Med Mol Imaging. 2021 Jan 21.
doi: 10.1007/s00259-021-05195-5. Online ahead of print.

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodríguez J, Snellman A, Suárez-Calvet M, Blennow K, Zetterberg H, Schöll M.
JAMA Neurol. 2021 Jan 11;78(4):396-406
doi: 10.1001/jamaneurol.2020.4986.

Head-to-head comparison of amplified plasmonic exosome Aβ42 platform and single-molecule array immunoassay in a memory clinic cohort.
Tanaka T, Ruifen JC, Nai YH, Tan CH, Lim CZJ, Zhang Y, Stephenson MC, Hilal S, Saridin FN, Gyanwali B, Villaraza S, Robins EG, Ihara M, Schöll M, Zetterberg H, Blennow K, Ashton NJ, Shao H, Reilhac A, Chen C.
Eur J Neurol. 2020 Dec 28;28(5):1479-1489
doi: 10.1111/ene.14704.

Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, Suárez-Calvet M, Zetterberg H, Blennow K, Schöll M.
Brain. 2021 Feb 12;144(1):325–339.
doi: 10.1093/brain/awaa399.  

Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M, Therriault J, Kang MS, Chamoun M, Schöll M, Zimmer ER, Gauthier S, Labbe A, Zetterberg H, Rosa-Neto P, Blennow K.
Brain. 2020 Dec 1;143(12):3793-3804.
doi: 10.1093/brain/awaa342.

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Suárez-Calvet M, Saha-Chaudhuri P, Lussier F, Kvartsberg H, Rial AM, Pascoal TA, Andreasson U, Schöll M, Weiner MW, Rosa-Neto P, Trojanowski JQ, Shaw LM, Blennow K, Zetterberg H; Alzheimer’s Disease Neuroimaging Initiative.
Mol Psychiatry. 2021 Feb;26(2):429–442.
doi: 10.1038/s41380-020-00923-z

Relevance of biomarkers across different neurodegenerative.
Ehrenberg AJ, Khatun A, Coomans E, Betts MJ, Capraro F, Thijssen EH, Senkevich K, Bharucha T, Jafarpour M, Young PNE, Jagust W, Carter SF, Lashley T, Grinberg LT, Pereira JB, Mattsson-Carlgren N, Ashton NJ, Hanrieder J, Zetterberg H, Schöll M, Paterson RW.
Alzheimers Res Ther. 2020 May 13;12(1):56.
DOI: 10.1186/s13195-020-00601-w PubMed

Steroid-responsive Encephalitis in Covid-19 Disease.
Pilotto A, Odolini S, Stefano Masciocchi S, Comelli A, Volonghi I, Gazzina S, Nocivelli S, Pezzini A, Focà E, Caruso A, Leonardi M, Pasolini MP, Roberto Gasparotti R, Francesco Castelli F, Ashton NJ, Blennow K, Zetterberg H, Padovani A.
Ann Neurol. 2020 Aug;88(2):423-427.
doi: 10.1002/ana.25783.  PubMed

Imaging biomarkers in neurodegeneration: current and future practices.
Young PNE, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, Venkataraman AV, Lissaman R, Jiménez D, Betts MJ, McGlinchey E, Berron D, O'Connor A, Fox NC, Pereira JB, Jagust W, Carter SF, Paterson RW, Schöll M.
Alzheimers Research & Therapy. 2020 Apr 27;12(1):49.
DOI: https://doi.org/10.1186/s13195-020-00612-7

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Schöll M, Massarweh G, Soucy JP, Höglund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stomrud E, Zetterberg H, Hansson O, Neto PR, Blennow K.
Lancet Neurol, 2020 May;19(5):422-433.
DOI: https://doi.org/10.1016/S1474-4422(20)30071-5

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders.
Ashton NJ, Hye A, Rajkumar AP, Leuzy A, Snowden S, Suárez-Calvet M, Karikari TK, Schöll M, La Joie R, Rabinovici GD, Höglund K, Ballard C, Hortobágyi T, Svenningsson P, Blennow K, Zetterberg H, Aarsland D.
Nat Rev Neurol. 2020 May;16(5):265-284
DOI: 10.1038/s41582-020-0348-0 PubMed

Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg.
Obrocki P, Khatun A, Ness D, Senkevich K, Hanrieder J, Capraro F, Mattsson N, Andreasson U, Portelius E, Ashton NJ, Blennow K, Schöll M, Paterson RW, Schott JM, Zetterberg H.
Alzheimers Research & Therapy. 2020 Feb 28;12(1):20.
DOI: 10.1186/s13195-020-00586-6. PubMed

FDG Uptake in the Basal Forebrain as Measured by Digital High-Resolution PET Is a Promising Marker of Basal Forebrain Degeneration in the Lewy Body Disease Spectrum: A Pilot Study.
Özden C, Frings L, Apostolova I, Lange C, Klutmann S, Adam G, Bannas P, Meyer PT, Grothe MJ, Buchert R.
Clin Nucl Med. 2020 Apr,45(4):261-266.
DOI: 10.1097/RLU.0000000000002960. PubMed

University College London/University of Gothenburg PhD course “Biomarkers in neurodegenerative diseases” 2019—course organization.
Khatun A, Paterson RW, Schöll M.
Alzheimer's Research & Therapy. 2020 Feb 4; 12 (1), 1-9.
DOI: 10.1186/s13195-020-0583-z PubMed

Disentangling Heterogeneity in Alzheimer's Disease and Related Dementias Using Data-Driven Methods.
Habes M, Grothe MJ, Tunc B, McMillan C, Wolk DA, Davatzikos C.
Biol Psychiatry. 2020 Jan 31; pii: S0006-3223(20)30050-0.
DOI: 10.1016/j.biopsych.2020.01.016

Lower 68Ga‐DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland-A proof-of-concept study.
Tjornstrand A, Casar-Borota O, Heurling KSchöll M, Gjertsson P, Himmelman J, Itsenko O, Ragnarsson O, Filipsson Nyström H.
Clinical Endocrinology. 2020 Jan 9; 92 (3), 222-231.
DOI: 10.1111/cen.14144 PubMed

Does early cognitive decline require the presence of both tau and amyloid-β?
Schöll M & Maass A.
2020 Jan 1; Brain 143 (1), 10-13.
DOI: 10.1093/brain/awz399 PubMed

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF- Alzheimer’s Disease Multimodal Biomarker Discovery Cohort.
Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Baker S, Buckley NJ, Ten Kate M, Scheltens P, Teunissen CE, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lléo A, Sala I, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Legido-Quigley C, Bertram L, Barkhof F, Zetterberg H, Morgan BP, Streffer J, Visser PJ, Lovestone S.
Journal of Alzheimer's Disease, 2020 Jan 22; 1-13.
DOI: 10.3233/JAD-190434 PubMed

PET Biomarkers for Tau Pathology.
Leuzy AHeurling KSchöll M.
Radiopharmaceuticals, 2020; 227-234.
DOI: https://doi.org/10.1007/978-3-030-27779-6_13

An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead.
Simrén J, Ashton NJ, Blennow K, Zetterberg H.
Current Opinion in Neurobiology. 2019 Dec; 61, 29-39.
DOI: 10.1016/j.conb.2019.11.019 PubMed

Salivary biomarkers for Alzheimer’s disease and related disorders.
Ashton NJ, Ide M, Zetterberg H, Blennow K.
Neurology and Therapy. 2019 Dec 8; (2), 83-94.
DOI:10.1007/s40120-019-00168-1 PubMed

Overeating Saturated Fat Promotes Fatty Liver and Ceramides Compared With Polyunsaturated Fat: A Randomized Trial.
Rosqvist F, Kullberg J, Ståhlman M, Cedernaes J, Heurling K, Johansson HE, Iggman D, Wilking H, Larsson A, Eriksson O, Johansson L, Straniero S, Rudling M, Antoni G, Lubberink M, Orho-Melander M, Borén J, Ahlström H, Risérus U.
J Clin Endocrinol Metab. 2019 Dec 1;104(12):6207-6219.
DOI: 10.1210/jc.2019-00160. PubMed

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.
Ashton NJ, Suárez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, Sanchez-Valle R, Molinuevo JL, Visser PJ, Blennow K, Hodges AK, Zetterberg H.
Alzheimers Res Ther. 2019 Nov 28;11(1):94.
DOI: 10.1186/s13195-019-0545-5. PubMed

Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.
Chatterjee P, Zetterberg H, Goozee K, Lim CK, Jacobs KR, Ashton NJ, Hye A, Pedrini S, Sohrabi HR, Shah T, Asih PR, Dave P, Shen K, Taddei K, Lovejoy DB, Guillemin GJ, Blennow K, Martins RN.
J Neuroinflammation. 2019 Oct 10;16(1):186.
DOI: 10.1186/s12974-019-1567-4. PubMed

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
Startin CM, Ashton NJ, Hamburg S, Hithersay R, Wiseman FK, Mok KY, Hardy J, Lleó A, Lovestone S, Parnetti L, Zetterberg H, Hye A; LonDownS Consortium, Strydom A.
Alzheimers Res Ther. 2019 Mar 21;11(1):26.
DOI: 10.1186/s13195-019-0477-0. PubMed

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals.
Benedet AL*, Ashton NJ*, Pascoal TA, Leuzy A, Mathotaarachchi S, Kang MS, Therriault J, Savard M, Chamoun M, Schöll M, Zimmer ER, Gauthier S, Labbe A, Zetterberg H, Blennow K, Neto PR.
Alzheimers Dement (Amst). 2019 Sep 27;11:679-689.
DOI: 10.1016/j.dadm.2019.08.002. eCollection 2019 Dec. PubMed

A walk through tau therapeutic strategies.
Jadhav S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, Buee L, Zilka N.
Acta neuropathol commun, 2019 Feb 15; 7, 22
DOI:10.1186/s40478-019-0664-z. PubMed

Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake.
Heurling K, Smith R, Strandberg OT, Schain M, Ohlsson T, Hansson O, Schöll M.
J Cereb Blood Flow Metab. 2019 Nov; 39(11):2223-2232.
DOI: 10.1177/0271678X18791430. PubMed

Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.
Thal DR, Ronisz A, Tousseyn T, Rijal Upadhaya A, Balakrishnan K, Vandenberghe R, Vandenbulcke M, von Arnim CAF, Otto M, Beach TG, Lilja J, Heurling K, Chakrabarty A, Ismail A, Buckley C, Smith APL, Kumar S, Farrar G, Walter J.
Acta Neuropathol Commun. 2019 Nov 14;7(1):178.
DOI: 10.1186/s40478-019-0837-9. PubMed

Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum.
Rajan, MR, Sotak, M, Barrenäs F, Shen T, Borkowski K, Ashton NJ, Biörserud C, Lindahl TL, Ramström S, Schöll M, Lindahl P, Fiehn O, Newman JW, Perkins R, Wallenius V, Lange S, Börgenson E.
Sci Rep, 2019 Oct 28; 9, 15385
DOI:10.1038/s41598-019-51673-0. PubMed

A Deep Learning Approach to MR-less Spatial Normalization for Tau PET Images. (2019).
Alvén JHeurling K, Smith R, Strandberg O, Schöll M, Hansson O, Kahl F, In: Shen D. et al. (eds) Medical Image Computing and Computer Assisted Intervention – MICCAI 2019. MICCAI 2019. Lecture Notes in Computer Science, vol 11765. Springer, Cham
DOI: 10.1007/978-3-030-32245-8_40

Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948.
Smith R, Schöll MLeuzy A, Jögi J, Ohlsson T, Strandberg O, Hansson O.
Eur J Nucl Med Mol Imaging. 2019 Oct 14; 1-13.
DOI: 10.1007/s00259-019-04496-0. PubMed

Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies.
Vogels TLeuzy A, Cicognola C, Ashton NJ, Smolek T, Novak M, Blennow K, Zetterberg H, Hromadka T, Zilka N, Schöll M.
Biol Psychiatry. 2019 Oct 3. pii: S0006-3223(19)31744-5.
DOI: 10.1016/j.biopsych.2019.09.019. PubMed

Prognostic value of Alzheimer’s biomarkers in mild cognitive impairment: the effect of age at onset.
Altomare D, Ferrari C, Caroli A, Galluzzi S, Prestia A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen CE, Wall A, Carter SF, Schöll M, Choo ILH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB.
Alzheimer’s Disease Neuroimaging Initiative, Journal of Neurology, 2019 Oct 1; 266 (10), 2535-2545.
DOI: 10.1007/s00415-019-09441-7. PubMed

Predicting MCI Status From Multimodal Language Data Using Cascaded Classifiers
Fraser KC, Lundholm Fors K, Eckerström M, Öhman F, Kokkinakis D.
Front. Aging Neurosci., 02 August 2019
DOI: 10.3389/fnagi.2019.00205 Pubmed

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.
Heurling KAshton NJLeuzy A, Zimmer ER, Blennow K, Zetterberg H, Eriksson J, Lubberink M, Schöll M.
Mol Cell Neurosci. 2019 Jun;97:34-42.
DOI: 10.1016/j.mcn.2019.02.001. PubMed

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies.
Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, Bullich S, Foley C, Lammertsma AA;
AMYPAD Consortium. EJNMMI Res. 2019 Mar 27;9(1):32.
DOI: 10.1186/s13550-019-0499-4. PubMed

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease.
Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A.
Sci Adv. 2019 Feb 6;5(2):eaau7220.
DOI: 10.1126/sciadv.aau7220. eCollection 2019 Feb PubMed

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.
Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R;
Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER Study. Hum Brain Mapp. 2019 Feb 1;40(2):638-651
DOI: 10.1002/hbm.24401PubMed

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease.
Mattsson N, Insel PS, Donohue M, Jögi J, Ossenkoppele R, Olsson T, Schöll M, Smith R, Hansson O.
Alzheimers Dement. 2019 Jan 24. pii: S1552-5260(18)33605-7.
DOI: 10.1016/j.jalz.2018.12.001. PubMed

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration.
Ashton NJLeuzy A, Lim YM, Troakes C, Hortobágyi T, Höglund K, Aarsland D, Lovestone S, Schöll M, Blennow K, Zetterberg H, Hye A.
Acta Neuropathol Commun. 2019 Jan 9;7(1):5.
DOI: 10.1186/s40478-018-0649-3. PubMed

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result.
Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN, Liu B, Newby D, Bazenet C, Kiddle SJ, Ward M, Newton B, Desai K, Tan Hehir C, Zanette M, Galimberti D, Parnetti L, Lleó A, Baker S, Narayan VA, van der Flier WM, Scheltens P, Teunissen CE, Visser PJ, Lovestone S.
Front Aging Neurosci. 2018 Dec 11;10:409.
DOI: 10.3389/fnagi.2018.00409. PubMed

Biomarkers for tau pathology.
Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, Jagust W.
Mol Cell Neurosci. 2018 Dec 7. pii: S1044-7431(18)30233-1
DOI: 10.1016/j.mcn.2018.12.001. PubMed

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease.
Mattsson N, Eriksson O, Lindberg O, Schöll M, Lampinen B, Nilsson M, Insel PS, Lautner R, Strandberg O, van Westen D, Zetterberg H, Blennow K, Palmqvist S, Stomrud E, Hansson O.
Neurobiol Aging. 2018 Nov;71:81-90.
DOI: 10.1016/j.neurobiolaging.2018.07.003. PubMed

Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.
Thal DR, Beach TG, Zanette M, Lilja J, Heurling K, Chakrabarty A, Ismail A, Farrar G, Buckley C, Smith APL.
Acta Neuropathol. 2018 Oct;136(4):557-567.
DOI: 10.1007/s00401-018-1897-9. PubMed

Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.
Gonzales MM, Insel PS, Nelson C, Tosun D, Schöll M, Mattsson N, Sacuiu S, Bickford D, Weiner MW, Mackin RS;
Alzheimer's Disease Neuroimaging Initiative. Int J Geriatr Psychiatry. 2018 Oct;33(10):1305-1311.
DOI: 10.1002/gps.4926. PubMed

No association of salivary total tau concentration with Alzheimer's disease.
Ashton NJ, Ide M, Schöll M, Blennow K, Lovestone S, Hye A, Zetterberg H.
Neurobiol Aging. 2018 Oct;70:125-127.
DOI: 10.1016/j.neurobiolaging.2018.06.014. PubMed

In vivo Detection of Alzheimer's Disease.
Leuzy AHeurling KAshton NJSchöll M, Zimmer ER.
Yale J Biol Med. 2018 Sep 21;91(3):291-300
PMCID: PMC6153625 PubMed

Discriminative accuracy of [18f] flortaucipir positron emission tomography for alzheimer disease vs other neurodegenerative disorders.
Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T, Jögi J, Tsai R, La Joie R, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, Choi JY, Ryu YH, Lyoo CH, Hansson O.
JAMA. 2018 Sep 18;320(11):1151-1162.
DOI: 10.1001/jama.2018.12917. PubMed

Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Schöll M, Hansson O, Teipel SJ;
Alzheimer’s Disease Neuroimaging Initiative. Brain. 2018 Sep 1;141(9):2755-2771
DOI: 10.1093/brain/awy189. PubMed

Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study.
Boersma GJ, Johansson E, Pereira MJ, Heurling K, Skrtic S, Lau J, Katsogiannos P, Panagiotou G, Lubberink M, Kullberg J, Ahlström H, Eriksson JW.
Horm Metab Res. 2018 Aug;50(8):627-639
DOI: 10.1055/a-0831-3620. PubMed

Update on biomarkers for amyloid pathology in Alzheimer's disease.
Ashton NJ, Schöll MHeurling K, Gkanatsiou E, Portelius E, Höglund K, Brinkmalm G, Hye A, Blennow K, Zetterberg H.
Biomark Med. 2018 Jul;12(7):799-812.
DOI: 10.2217/bmm-2017-0433. PubMed

Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study.
Thordardottir S, Rodriguez-Vieitez E, Almkvist O, Ferreira D, Saint-Aubert L, Kinhult-Ståhlbom A, Thonberg H, Schöll M, Westman E, Wall A, Eriksdotter M, Zetterberg H, Blennow K, Nordberg A, Graff C.
Alzheimer's research therapy, 2018 May 10; 10(1):45
DOI: 10.1186/s13195-018-0374-y PubMed

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies.
Smith R, Schöll M, Londos E, Ohlsson T, Hansson O.
Sci Rep, 2018 Mar 16, 8, 4717
DOI:10.1038/s41598-018-23041-x PubMed

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity.
Palmqvist S*, Schöll M*, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O. *contributed equally.
Nature Communications. 2017 Oct 31;8(1):1214.
DOI: 10.1038/s41467-017-01150-x. PubMed

Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease.
Schöll M, Ossenkoppele R, Strandberg O, Palmqvist S; Swedish BioFINDER study, Jögi J, Ohlsson T, Smith R, Hansson O.
Brain. 2017 Sep 1;140(9):2286-2294.
DOI: 10.1093/brain/awx171 PubMed

Quantitative positron emission tomography in brain research.
Heurling KLeuzy A, Jonasson M, Frick A, Zimmer ER, Nordberg A, Lubberink M.
Brain Res. 2017 Sep 1;1670:220-234.
doi: 10.1016/j.brainres.2017.06.022. PubMed

In vivo retention of 18F-AV-1451 in corticobasal syndrome.
Smith R, Schöll M, Widner H, Westen D, Svenningsson P, Hägerström D, Ohlsson T, Jögi J, Nilsson C, Hansson O.
Neurology. 2017 Aug 22, 89 (8) 845-853;
DOI:10.1212/WNL.0000000000004264 PubMed

Linking Amyloid-β and Tau Deposition in Alzheimer Disease.
Vemuri P, Schöll M.
JAMA Neurol.2017 Jul 1;74(7):766–768.
DOI: 10.1001/jamaneurol.2017.0323 PubMed

AAIC2021 abstracts

Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation.
Alexis Moscoso, Thomas K Karikari, Michel J Grothe, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow and Michael Schöll.

Association of deep-learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases.
Meera Srikrishna, Nicholas J Ashton, Joana B Pereira, Rolf A Heckemann, Danielle van Westen, Giovanni Volpe, Joel Simrén, Anna Zettergren, Silke Kern, Lars-Olof Wahlund, Bibek Gyanwali, Saima Hilal, Joyce R Chong, Henrik Zetterberg, Kaj Blennow, Eric Westman, Christopher Chen, Ingmar Skoog and Michael Schöll.

Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer's disease neuropathology.
Michel J Grothe, Alexis Moscoso, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow and Michael Schöll.

Brain Atrophy and White Matter Hyperintensities are Independently Associated with Plasma Neurofilament Light Chain in an Asian Cohort of Patients with Mixed Pathology.
Joyce R Chong, Nicholas J Ashton, Thomas K Karikari, Saima Hilal, Francis Saridin, Tomotaka Tanaka, Michael Schöll, Kaj Blennow, Henrik Zetterberg, Mitchell Kim Peng Lai and Christopher Chen.

Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: biomarkers of synaptic density in Alzheimer’s disease.
Adam P Mecca, Nicholas J Ashton, Ming-Kai Chen, Ryan S O'Dell, Mika Naganawa, Takuya Toyonaga, Wenzhen Zhao, Nabeel B Nabulsi, Ann Brinkmalm, Hlin Kvartsberg, Michael Schöll, Amy F T Arnsten, Yiyun Huang, Kaj Blennow, Henrik Zetterberg, Richard E Carson, Christopher H van Dyck and Johanna Nilsson.

CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative disease: a systematic review and meta-analysis. 
Elisa Lancini, Franziska Bart, Lena Haag, Maren Rühling, Nicholas J Ashton, Henrik Zetterberg, Emrah Düzel, Dorothea Hämmerer and Matthew Betts.

CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in cognitively unimpaired healthy elderly with a parental history of Alzheimer’s disease. 
Judes Poirier, Nathalie I V Nilsson, Anne Labonté, Pedro Rosa-Neto, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, John Breitner, Sylvia Villeneuve and Cynthia Picard; Prevent-AD Research Group.

Current Status and Quantitative Results of the AMYPAD Prognostic and Natural History Study.
Juan Domingo Gispert, Isadora Lopes Alves, Katherine R Gray, Christopher Buckley, Lyduine E Collij, Fiona Heeman, Gemma Salvadó, David Vállez García, Peter Connelly, Claire Boutoleau-Bretonnière, Florence Pasquier, Julien Dumurgier, Audrey Gabelle, Bruno Dubois, Pierre Payoux, Oriol Grau-Rivera, Pablo Martinez-Lage, Mercè Boada, Marta Marquié, Rik Vandenberghe, Bernard J Hanseeuw, Miia Kivipelto, Michael Schöll, Philip Scheltens, Giovanni B Frisoni, Craig W Ritchie, Bruno Vellas, Andrew W Stephens, Lisa Ford, Jose Molinuevo, Pieter Jelle Visser,Gill Farrar, Frederik Barkhof; AMYPAD Consortium.

Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers.
Shorena Janelidze, Sebastian Palmqvist, Antoine Leuzy, Erik Stomrud, Inge M W Verberk, Henrik Zetterberg, Nicholas J Ashton, Niklas Mattsson-Carlgren, Pedro Pesini, Leticia Sarasa, Jose A Allué, Charlotte E Teunissen, Jeffrey L Dage, Kaj Blennow and Oskar Hansson. 

Disentangling Disease Heterogeneity from Neuroimaging Data via Adaptive Distribution Modeling Based Collaborative Clustering.
Hangfan Liu, Michel J Grothe, Tanweer Rashid, Miguel Labrador-Espinosa, Jon B Toledo and Mohamad Habes.

Distinctive effect of biological sex in AD-related CSF and plasma biomarkers.
Marta Milà-Alomà, Ann Brinkmalm, Juan Lantero Rodriguez, Thomas K Karikari, Nicholas J Ashton, Hlin Kvartsberg, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sánchez-Benavides, Eider M Arenaza-Urquijo, Anna Brugulat-Serrat, Muge Akinci, José Maria González-de-Echávarri, Carolina Minguillón, Karine Fauria, Ivonne Suridjan, Gwendlyn Kollmorgen, Erik Stoops, Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, Jose Molinuevo and Marc Suarez-Calvet; the ALFA study.

Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: an EEG-fMRI study.
Roberta Lizio, Susanna Lopez, Harald Hampel, Patrizia Andrea Chiesa, Claudio Del Percio, Giuseppe Noce, Stefan J Teipel, Gabriel González-Escamilla, Hovagim Bakardjian, Enrica Cavedo, Simone Lista, Andrea Vergallo, Pablo Lemercier, Giuseppe Spinelli, Michel J Grothe, Marie-Claude Potier, Fabrizio Stocchi, Raffaele Ferri, Marie-Odile Habert, Bruno Dubois and Claudio Babiloni; INSIGHT-preAD study group.

Impact of reduced injected dose on the quantification of [18F]RO948 and [18F]Flortaucipir PET for in vivo tau pathology.
Peter Young, Wesley P Thomas, Jan Axelsson, Jakob Himmelmann, Pablo Aguilar Dominguez, Tomas Ohlsson, Oskar Hansson, Mark Lubberink, Sandra Sanabria Bohorquez, Anna Rieckmann, Suzanne L Baker and Michael Schöll.

In vivo amyloid staging in individuals with subjective cognitive decline in DELCODE study.
Fedor Levin, Michel J Grothe, Martin Dyrba, Henning Boecker, Marcel Daamen, Catharina Lange, Katharina Buerger, Michael T Heneka, Christoph Laske, Oliver Peters, Josef Priller, Alfredo Ramirez, Anja Schneider, Annika Spottke, Michael Wagner, Emrah Düzel, Frank Jessen and Stefan J Teipel; the DELCODE study group.

Mass spectrometric measurement of six site-specific tau phosphorylations in CSF and blood of Alzheimer’s disease patients.
Laia Montoliu-Gaya, Nicholas J Ashton, Andréa Lessa Benedet, Juan Lantero Rodriguez, Gunnar Brinkmalm, Thomas K Karikari, Silke Kern, Pedro Rosa-Neto, Henrik Zetterberg, Kaj Blennow and Johan Gobom.

Microglial activation and tau propagate jointly across Braak stages.
Tharick A Pascoal, Andréa Lessa Benedet, Nicholas J Ashton, Min Su Kang, Joseph Therriault, Mira Chamoun, Firoza Z Lussier, Cécile Tissot, Julie Ottoy, Sulanta Mathotaarachchi, Jenna Stevenson, Gassan Massarweh, Michael Schöll, Jean-Paul Soucy, Kaj Blennow, Henrik Zetterberg, Serge Gauthier and Pedro Rosa-Neto.

Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up.
Nelly Kanberg, Joel Simrén, Arvid Éden, Lars-Magnus Andersson, Staffan Nilsson, Nicholas J Ashton, Pär-Daniel Sundvall, Bengt Nellgård, Kaj Blennow, Henrik Zetterberg and Magnus Gisslén.

Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a community-based population of 70-year olds.
Anna Dittrich, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Anna Zettergren, Joel Simrén, Michael Schöll, Eric Westman, Ingmar Skoog and Silke Kern.

Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients.
Michelle Gerards, Ann-Katrin Schild, Dix U Meiberth, Ayda Rostamzadeh, Jörg Janne Vehreschild, Sebastian Wingen-Heimann, Pamela V Martino Adami, Oezguer A Onur, Alfredo Ramirez, Thomas K Karikari, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Franziska Maier and Frank Jessen.

Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer’s disease.
Daniel Alcolea, Constance Delaby, Laia Muñoz, Soraya Torres, Teresa Estellés, Nuole Zhu, Isabel Barroeta, Maria Carmona-Iragui, Ignacio Illán-Gala, Miguel A Santos-Santos, Miren Altuna, Isabel Sala, Belen Sánchez-Saudinós, Laura Videla, Sílvia Valldeneu, Andrea Subirana, Jordi Pegueroles, Christophe Hirtz, Jérôme Vialaret, Sylvain Lehmann, Thomas K Karikari, Nicholas J Ashton, Kaj Blennow, Henrik Zetterberg, Olivia Belbin, Rafael Blesa, Jordi Clarimón, Juan Fortea and Alberto Lleó.

Plasma glial fibrillary acidic protein is an early and specific marker of amyloid-β pathology in Alzheimer’s disease.
Joana B Pereira, Shorena Janelidze, Ruben Smith, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Henrik Zetterberg, Erik Stomrud, Nicholas J Ashton, Kaj Blennow and Oskar Hansson.

Plasma P-tau181 and NfL are central nodes in a network of diagnostic, biomarker, and demographic data.
Brandon E Frank, Madeline Ally, Bailee Brekke, Henrik Zetterberg, Kaj Blennow, Michael Sugarman, Nicholas J Ashton, Thomas K Karikari, Yorghos Tripodis, Ann C McKee, Thor D Stein, Brett M Martin, Joseph Palmisano, Eric Steinberg, Irene Simkin, Katherine W Turk, Andrew Budson, Maureen K O'Connor, Rhoda Au, Wendy Qiu, Lee E Goldstein, Ronald J Killiany, Neil W Kowall, Jesse Mez, Robert A Stern and Michael L Alosco.

Plasma p-Tau181 and p-Tau231 offer complementary information to identify Alzheimer's disease pathophysiology.
Pamela C L Ferreira, Wagner Scheeren Brum, João Pedro Ferrari-Souza, Cécile Tissot, Bruna Bellaver, Joseph Therriault, Andréa Lessa Benedet, Nicholas J Ashton, Stijn Servaes, Firoza Z Lussier, Mira Chamoun, Jenna Stevenson, Nesrine Rahmouni, Serge Gauthier, Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, Eduardo R Zimmer, Thomas K Karikari, Pedro Rosa-Neto and Tharick A Pascoal.

Plasma p-tau231 in the Alzheimer’s disease continuum: a multi-cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application.
Nicholas J Ashton, Thomas K Karikari, Juan Lantero Rodriguez, Andréa Lessa Benedet, Anniina Snellman, Tharick A Pascoal, Serge Gauthier, Pedro Rosa-Neto, Clifford R Jack Jr., Ronald C Petersen, Michelle M Mielke, Pratishtha Chatterjee, Ralph N Martins, Madhav Thambisetty, Vijay R Varma, Susan M Resnick, Nick C Fox, Antoinette O'Connor, Agathe Vrillon, Claire Paquet, Sylvia Villeneuve, Judes Poirier, Prevent-AD Research Group, Doug R Galasko, Marta Milà-Alomà, Carolina Minguillón, Karine Fauria, Marc Suarez-Calvet, Eugeen Vanmechelen, Henrik Zetterberg and Kaj Blennow.

Tau pathology progression across PET-based stages of regional amyloid deposition.
Alexis Moscoso, Michel J Grothe and Michael Schöll.

Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum.
Joel Simrén, Andréa Lessa Benedet, Nicholas J Ashton, Tharick A Pascoal, Henrik Zetterberg, Pedro Rosa-Neto and Kaj Blennow.

The association of Alzheimer’s disease and cerebrovascular disease biomarkers towards the neurodegeneration of the cholinergic pathways.
Nira Cedres, Daniel Ferreira, Milan Nemy, Alejandra Machado, Joana B Pereira, Lars-Olof Wahlund, Anna Zettergren, Stefan J Teipel, Michel J Grothe, Maria Eriksdotter, Olga Stepankova, Lenka Vyslouzilova, Kaj Blennow, Henrik Zetterberg, Silke Kern, Ingmar Skoog and Eric Westman.

When is a biomarker an AD biomarker? – Face versus construct validity and practical implications for differential application.
Michael Schöll.

AD/PD 2021 abstracts

Oral presentations: 

Nicholas J. Ashton – Novel plasma p-tau231 in Alzheimer’s disease: Early increase indicates utility for preventive trial selection

Alexis Moscoso – PET-measured progression of tau pathology across in-vivo stages of regional amyloid deposition 

Peter Young – Impact of reduced injected dose on the pet quantification of [18F]RO948 to assess tau pathology in vivo

Thomas Vogels – AAV vectors to study the functional consequences of neuronal and astrocytic tau pathology using in vivo 2-photon imaging

Meera Srikrishna – First-level assessment of neurodegeneration using deep-learning based brain CT segmentations and blood-derived measures of neurofilament light 

Michel J. Grothe – Data-driven identification of distinct cognitive subtypes in Parkinson’s disease dementia: Associations with clinical, genetic, and biomarker characteristics

Anniina Snellman – Novel total tau assays: Exploring tau fragments in alzheimer’s disease and other neurological disorders 

Posters:

Neuropathologic correlates of elecsys-derived cerebrospinal fluid biomarkers of Alzheimer’s disease in comparison to a novel plasma-based p-tau181 biomarker 
M. Grothe, N. Ashton, A. Moscoso, H. Zetterberg, K. Blennow, M. Schöll 
 
Association of blood phosphorylated tau181 and neurofilament light with progressive neurodegeneration in Alzheimer disease 
A. Moscoso, M. Grothe, N. Ashton, H. Zetterberg, K. Blennow, M. Schöll

Simultaneous measurement of site-specific tau phosphorylations in blood for early and accurate diagnosis of Alzheimer´s disease 
L. Montoliu-Gaya, N. Ashton, M. Sauer, J. Lantero Rodriguez, G. Brinkmalm, T. Karikari, S. Kern, H. Zetterberg, K. Blennow, J. Gobom

Plasma inflammatory and neurodegeneration markers and disease progression in Lewy bodies disorders 
A. Pilotto, A. Imarisio, E. Garraffa, F. Conforti, A. Scalvini, S. Masciocchi, S. Nocivelli, R. Turrone, S. Gipponi, E. Cottina, B. Borroni, M. Rizzetti, M. Pizzi, A. Bellucci, L. Bonanni, H. Zetterberg, N. Ashton, A. Hye, A. Padovani

Alternative protocols to support blood collection in challenging pre-analytical conditions 
J. Simrén, K. Blennow, H. Zetterberg, N. Ashton

Cognitive impairment in PSP relates to degeneration of the nucleus basalis of Meynert 
S. Rogozinski, G. Respondek, M. Grothe, J.B. Pereira, G. Höglinger 

AAIC2020 abstracts

Poster- Differential effects of APOE2 and APOE4 alleles on PET-measured amyloid-β and tau deposition in older individuals without dementia.
Michel J. Grothe, Gemma Salvadó, Colin Groot, Alexis Moscoso, Juan Domingo Gispert, Michael Schöll and Rik Ossenkoppele.

Poster- Association of plasma neurofilament light chain (pNfL) with neuroimaging markers of neurodegeneration and cerebrovascular disease.
Joyce R Chong, Kaj Blennow, Henrik Zetterberg, Michael Schöll, Nicholas J Ashton, Thomas K Karikari, Francis Saridin, Tomotaka Tanaka, Saima Hilal, Mitchell Kim Peng Lai and Christopher Chen.

Poster- Plasma-based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer’s disease. 
Antoine Leuzy, Nicholas J Ashton, Thomas K Karikari, Joel Simrén, Gustav Mårtensson, Andréa Lessa Benedet, Abdul Hye, Michael Schöll, Patrizia Mecocci, Bruno Vellas, Magda Tsolaki, Iwona Kłoszewska, Simon Lovestone, Dag Aarsland, Niklas Mattsson, Oskar Hansson, Eric Westman, Kaj Blennow and Henrik Zetterberg.

Poster- Current Status and Quantitative Results of the AMYPAD Prognostic and Natural History Study.
Isadora Lopes Alves, Juan Domingo Gispert, Katherine R Gray, Lyduine Collij, Fiona Heeman, Gemma Salvadó, Laure Saint-Aubert, Pierre Payoux, Bruno Vellas, Claire Boutoleau-Bretonnière, Audrey Gabelle, Florence Pasquier, Julien Dumurgier, Bruno Dubois, Peter Connelly, Oriol Grau-Rivera, Pablo Martinez-Lage, Mercè Boada, Marta Marquie, Rik Vandenberghe, Bernard Hanseeuw, Miia Kivipelto, Michael Schöll, Giovanni B Frisoni, Philip Scheltens, Craig W. Ritchie, Andrew W Stephens, Christopher Buckley, Lisa Ford, Jose Luis Molinuevo, Gill Farrar and Frederik Barkhof.

Poster- CT-based brain segmentation and volumetry using deep learning methods.
Meera Srikrishna, Joana B Pereira, Rolf A Heckemann, Giovanni Volpe, Anna Zettergren, Silke Kern, Eric Westman, Ingmar Skoog and Michael Schöll.

Poster- Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter
Alexis Moscoso, A.J. Whitman,  Suzanne L. Baker, Renaud La Joie, Tharick A. Pascoal, Pedro Rosa-Neto, Gil D. Rabinovici, William J. Jagust, Michel Grothe  and Michael Schöll.

SCR2-09-04 Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology. 
Nicholas J Ashton, Andréa Lessa Benedet, Tharick A. Pascoal , Hlin Kvartsberg, Thomas K Karikari, Michael Schöll, Erik Stoops, Cindy Francois, Eugeen Vanmechelen, Sulantha Mathotaarachchi, Melissa Savard, Joseph Therriault, Mira Chamoun, Henrik Zetterberg, Pedro Rosa-Neto and Kaj Blennow

Poster- Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s disease.
Adam P. Mecca, Nicholas J Ashton, Ming-Kai Chen, Ryan S. O'Dell, Mika Naganawa, Takuya Toyonaga,; Joanna E. Harris, Hugh H. Bartlett, Emmie R. Banks, Victoria L. Kominek, Nabeel B. Nabulsi, Soheila Najafzadeh, Brent C. Vander Wyk, Ann Brinkmalm, Hlin Kvartsberg, Michael Schöll, Amy F. T. Arnsten, Yiyun Huang, Kaj Blennow, Henrik Zetterberg, Richard E. Carson and Christopher H. van Dyck.

Poster- Clinical and neurodegenerative features associated with amyloid-β-negative medial temporal tau deposition as measured by multimodal PET imaging.
Michel J. Grothe, Alexis Moscoso and Michael Schöll.

Poster- Association of white matter hyperintensities with sub-threshold amyloid accumulation. 
Alexis Moscoso, David Rey-Bretal, Jesús Silva-Rodríguez, Michel Grothe, Michael Schöll and Pablo Aguiar.

ODO2-04-04 Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology.
Nicholas J Ashton, Andréa Lessa Benedet, Tharick A. Pascoal , Hlin Kvartsberg, Thomas K Karikari, Michael Schöll, Erik Stoops, Cindy Francois, Eugeen Vanmechelen, Sulantha Mathotaarachchi, Melissa Savard, Joseph Therriault, Mira Chamoun, Henrik Zetterberg, Pedro Rosa-Neto and Kaj Blennow.

Poster- Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET.
David M Cash, Pawel J Markiewicz, Jieqing Jiao, William Coath, Marc Modat, Christopher A Lane, Thomas D Parker, Sarah E Keuss, Sarah M Buchanan, Ninon Burgos, John Dickson, Anna Barnes, Jorge Cardoso, Isadora Lopes Alves, Frederik Barkhof, David L Thomas, Daniel Beasley, Andrew Wong, Michael Schöll, Marcus Richards, Sebastien Ourselin, Nick C Fox and Jonathan M Schott

Poster- Plasma-based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer’s disease. 
Antoine Leuzy, Nicholas J Ashton, Thomas K Karikari, Joel Simrén, Gustav Mårtensson, Andréa Lessa Benedet, Abdul Hye, Michael Schöll, Patrizia Mecocci, Bruno Vellas, Magda Tsolaki, Iwona Kłoszewska, Simon Lovestone, Dag Aarsland, Niklas Mattsson, Oskar Hansson, Eric Westman, Kaj Blennow and Henrik Zetterberg.

SCR2-09-04 Cerebrospinal fluid tau biomarkers in the prediction and concordance of neurofibrillary tangle and amyloid pathology
Nicholas J Ashton, Andréa Lessa Benedet, Tharick A. Pascoal , Hlin Kvartsberg, Thomas K Karikari, Michael Schöll, Erik Stoops, Cindy Francois, Eugeen Vanmechelen, Sulantha Mathotaarachchi, Melissa Savard, Joseph Therriault, Mira Chamoun, Henrik Zetterberg, Pedro Rosa-Neto and Kaj Blennow.

Poster- Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer’s disease in the absence of AT(N) classification as the reference standard.
Joel Simrén, Antoine Leuzy, Thomas K Karikari, Abdul Hye, Niklas Mattsson, Oskar Hansson, Michael Schöll, Patrizia Mecocci, Bruno Vellas, Magda Tsolaki, Iwona Kloszewska, Hilkka Soininen, Simon Lovestone, Dag Aarsland, Eric Westman, Kaj Blennow, Henrik Zetterberg, Nicholas J Ashton.

Poster- Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET.
David M Cash, Pawel J Markiewicz, Jieqing Jiao, William Coath, Marc Modat, Christopher A Lane, Thomas D Parker, Sarah E Keuss, Sarah M Buchanan, Ninon Burgos, John Dickson, Anna Barnes, Jorge Cardoso, Isadora Lopes Alves, Frederik Barkhof, David L Thomas, Daniel Beasley, Andrew Wong, Michael Schöll, Marcus Richards, Sebastien Ourselin, Nick C Fox and Jonathan M Schott.

Poster- Amyloid-β, tau, synaptic, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimer’s continuum.
Marc Suárez-Calvet, Marta Milà-Alomà, Gemma Salvadó, Juan Domingo Gispert, Natalia Vilor-Tejedor, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sanchez-Benavides, Eider M Arenaza-Urquijo, Marta Crous-Bou, José Maria González-de-Echávarri, Carolina Minguillón, Karine Fauria, Maryline Simon, Gwen Kollmorgen, Juan Rodríguez-Lantero11,12; Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Jose Luis Molinuevo.

SCR2-01-04 The effect of physical activity on CSF biomarkers of Alzheimer’s disease differs between men and women. 
Marta Milà-Alomà, Gemma Salvadó, Juan Domingo Gispert, Natalia Vilor-Tejedor, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sanchez-Benavides, Eider M Arenaza-Urquijo, Marta Crous-Bou, José Maria González-de-Echávarri, Carolina Minguillón, Karine Fauria, Maryline Simon, Gwendlyn Kollmorgen, Juan Rodríguez-Lantero, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Jose Luis Molinuevo and Marc Suárez-Calvet.

Poster- Serum NfL as a predictor of disease progression in Dementia with Lewy bodies.
Andrea Pilotto, Alberto Imarisio, Francesca Conforti, Alessandro Lupini, Giuliana Giannì, Stefano Gipponi, Elisabetta Cottini, Stefano Masciocchi, Sara Nocivelli, Roberto Grasso, Rosanna Turrone, Barbara Borroni, Maria Cristina Rizzetti, Laura Bonanni, Marina Pizzi, Arianna Bellucci, Emirena Garrafa, Henrik Zetterberg, Abdul Hye, Nicholas J Ashton and Alessandro Padovani.

Poster- CSF phosphorylated tau-217 is increased in Alzheimer’s and Creutzfeldt-Jakob diseases, and correlates with amyloid pathology. 
Andreja Emeršič, Thomas K Karikari, Juan Rodríguez-Lantero, Nicholas J Ashton, Uros Rot, Milica G Kramberger, Saša Čučnik, Henrik Zetterberg and Kaj Blennow.

SFRS2-01-03 Alzheimer’s Disease Biomarker Roadmap 2020: second-generation tau PET tracers.
Gerard N Bischof, Alessandra Dodich, Nicholas J Ashton, Marina Boccardi, Henryk Barthel, Maria C. Carrillo, Konstantinos Chiotis, Julie Corre, Jean-François Démonet, Anton F. Gietl, Keith A. Johnson, Oskar Hansson, Antoine Leuzy, Marco Lorenzi, Agneta K Nordberg, Rik Ossenkoppele, Gil D. Rabinovici, Osman Ratib, Osama Sabri, Valerie Treyer, Paul G. Unschuld, Victor L L Villemagne, Emma E. Wolters, Bengt Winblad,
Giovanni B. Frisoni, Valentina Garibotto and Alexander Drzezga.

SFRS2-01-04 Alzheimer’s Disease Biomarker Roadmap 2020: fluids biomarkers. 
Nicholas J Ashton, Antoine Leuzy, Thomas K Karikari, Alessandra Dodich, Marina Boccardi, Henryk Barthel, Gerard N Bischof, Maria C. Carrillo, Konstantinos Chiotis et al.

ODO2-01-04 The effect of physical activity on CSF biomarkers of Alzheimer’s disease differs between men and women
Marta Milà-Alomà, Gemma Salvadó, Juan Domingo Gispert, Natalia Vilor-Tejedor, Oriol Grau-Rivera, Aleix Sala-Vila, Gonzalo Sanchez-Benavides, Eider M Arenaza-Urquijo, Marta Crous-Bou, José Maria González-de-Echávarri, Carolina Minguillón, Karine Fauria, Maryline Simon, Gwendlyn Kollmorgen, Juan Rodríguez-Lantero, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Jose Luis Molinuevo and Marc Suárez-Calvet.

SFRS2-01-01 Alzheimer’s Disease Biomarker Roadmap 2020: time for tau. 
Alessandra Dodich, Marina Boccardi, Nicholas J Ashton, Henryk Barthel, Gerard N Bischof, Maria C. Carrillo, Konstantinos Chiotis et al.

Poster- Identification of Plasma Proteome Signatures Associated with ATN framework Using SOMAscan.
Liu Shi, Sarah Westwood, Alison L Baird, Noel Buckley, Valerija Dobricic, Fabian Kilpert, Shengjun Hong, Andreas Franke, Abdul Hye, Nicholas J Ashton et al.

SO2-03-02 Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline.
Juan Lantero Rodriguez, Thomas K Karikari, Marc Suárez-Calvet, Claire Troakes, Andrew King, Andreja Emeršič, Dag Aarsland, Abdul Hye, Henrik Zetterberg, Kaj Blennow and Nicholas J Ashton.

SFRS2-01-02 Alzheimer’s Disease Biomarker Roadmap 2020: [18F]flortaucipir. 
Emma E. Wolters, Konstantinos Chiotis, Alessandra Dodich, Nicholas J Ashton, Henryk Barthel, Gerard N Bischof, Marina Boccardi, Maria C. Carrillo, Julie Corre, Jean-François Démonet, Alexander Drzezga, Anton F. Gietl, Oskar Hansson, Keith A. Johnson, Antoine Leuzy, Marco Lorenzi, Gil D. Rabinovici, Osman Ratib, Osama Sabri, Valerie Treyer, Paul G. Unschuld, Victor L L Villemagne, Bengt Winblad, Giovanni B. Frisoni, Valentina Garibotto, Agneta K Nordberg  and Rik Ossenkoppele.

SO2-01-03 Microglial activation indexed by [11C]PBR28 is associated with synaptic depletion in the Alzheimer’s disease spectrum. 
Andréa Lessa Benedet, Nicholas J Ashton, Tharick A. Pascoal , Ann Brinkmalm, Johanna Nilsson, Hlin Kvartsberg, Sulantha Mathotaarachchi, Melissa Savard, Joseph Therriault, Cécile Tissot, Mira Chamoun, Kaj Blennow, MD, Henrik Zetterberg and Pedro Rosa-Neto.

SO2-01-06 SNAP25 reflects amyloid- and tau-related synaptic damage: associations between PET, VBM and cerebrospinal fluid biomarkers of synaptic disfunction in the Alzheimer’s disease spectrum
Andréa Lessa Benedet, Nicholas J Ashton, Tharick A. Pascoal ,Ann Brinkmalm, Johanna Nilsson, Hlin Kvartsberg, Sulantha Mathotaarachchi, Mélissa Savard, Joseph Therriault, Cécile Tissot, Mira Chamoun, Henrik Zetterberg, Kaj Blennow and Pedro Rosa-Neto.

Poster- Quantification of tau phosphorylated at threonine 217 using a novel ultrasensitive immunoassay distinguishes Alzheimer’s disease from healthy controls 
Hlin Kvartsberg, Jozef Hanes, Andréa Lessa Benedet, Nicholas J Ashton, Tharick A. Pascoal, Pedro Rosa-Neto, Oskar Hansson, Henrik Zetterberg, Norbert Zilka and Kaj Blennow.

Grants and Awards

Grants as Principal or Co-Investigator

Current funding

  • (Knut and Alice Wallenberg Foundation) Wallenberg Centre for Molecular and Translational Medicine
  • The Swedish Research Council
  • The Swedish Alzheimer Foundation
  • SciLifeLab National COVID-19 Research Program funded by Knut and Alice Wallenberg Foundation
  • Hjärnfonden (NeuroCovid)
  • Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond (NeuroCovid)
  • Sahlgrenska Academy (Grant for PhD student, grant for postdoc, grant for hosting guest professor)
  • ALF Västra Götaland Region
  • The Association FTD
  • FORTE
  • Björnsson Foundation
  • Magnus Bergvalls Stiftelse
  • ARUK Pump award (3000 GBP), Kerstin Sander PI, co-PI

Awards

  • Birger Karlssons vetenskapspris (Royal Society of Arts and Sciences in Gothenburg)
  • Queen Silvia Prize to a Young Alzheimers Researcher (Swedish Alzheimer Association, 2018)
  • Best oral presentation (Alzheimer's Association)
  • Full conference award (Alzheimer's Association)
  • Best abstract and presentation (Swedish Brain Power)
  • Karolinska Institutet’s KID award (for co-financing a PhD student)

Team Members' Grants and Awards

Grants

Nicholas Ashton

- ARUK Network
- Alzheimerfonden
- Demensfonden
- Hjärnfonden
- Agneta Prytz-Folkes and Gösta Folkes
- Stiftelsen För Gamla Tjänarinnor
- Anna-Lisa and Bror Björnssons stiftelse 
- Gun och Bertil Stohnes 

Kerstin Heurling

- Magnus Bergvalls Stiftelse
- SLS Projektanslag

Antoine Leuzy

- Anna-Lisa och Bror Björnssons Stiftelse
- Gun och Bertil Stohnes Stiftelse

Alexis Moscoso

- Stiftelsen för Gamla Tjänarinnor

Meera Srikrishna

- Gun och Bertil Stohnes Stiftelse
- Stiftelsen för Gamla Tjänarinnor
- Stiftelsen Systrarna Greta Johansson och Brita Anderssons Minnesfond 
- Anna-Lisa och Bror Björnssons stiftelse 

Thomas Vogels

- Stiftelsen För Gamla Tjänarinnor
- Gun och Bertil Stohnes Stiftelse
- Demensfonden

Peter Young

- Anna-Lisa och Bror Björnssons stiftelse
- NMMP Facilitation Grant
- GU Travel Grant
- Gun och Bertil Stohnes Stiftelse

Fredrik Öhman

- Anna-Lisa och Bror Björnssons Stiftelse
- Stiftelsen Handlanden Hjalmar Svensson
- Carin Manneheimers Prize for Junior Researchers
- Gun och Bertil Stohnes Stiftelse
- Fredrik och Ingrid Thurings Stiftelse
- Sahlgrenska Akademins resestipendie 
- Sveriges Neuropsykologers Förening 

Awards

Nicholas Ashton
- Queen Silvia Prize to a Young Alzheimers Researcher (Swedish Alzheimer Association, 2021)